ptupb Search Results


ptupb  (MedChemExpress)
92
MedChemExpress ptupb
Ptupb, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ptupb/product/MedChemExpress
Average 92 stars, based on 1 article reviews
ptupb - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier
ptupb (30 mg/kg/d)  (Durect Corporation)
90
Durect Corporation ptupb (30 mg/kg/d)
Suppression of debris-stimulated ovarian tumor growth by <t>PTUPB.</t> Percent survival of mice coinjected intraperitoneally with (A) paclitaxel- or (B) carboplatin-generated ID8 debris (9 × 105 dead cells) and ID8 living cells (1 × 106), or (C) coinjected orthotopically with paclitaxel-generated ID8 debris (9 × 105 dead cells) and ID8 living cells (1 × 106). Image shows representative orthotopic tumors on day 62 postinjection. (Scale bar,1 <t>cm.)</t> <t>Systemic</t> treatment with PTUPB (30 mg/kg/d) or control initiated 4 wk postinjection. n = 4–5 mice per group. Kaplan–Meier analysis and log-rank testing indicated significantly prolonged survival in mice treated with PTUPB compared with control in the (A) paclitaxel-generated (log-rank test = 9.70, *P = 0.0018) and (B) carboplatin-generated (log-rank test = 9.85, *P = 0.0017) debris-stimulated intraperitoneal ovarian tumor models, as well as the (C) paclitaxel-generated debris-stimulated orthotopic ovarian tumor model (log-rank test = 7.91, *P = 0.005).
Ptupb (30 Mg/Kg/D), supplied by Durect Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ptupb (30 mg/kg/d)/product/Durect Corporation
Average 90 stars, based on 1 article reviews
ptupb (30 mg/kg/d) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
ptupb  (Federation of European Neuroscience Societies)
90
Federation of European Neuroscience Societies ptupb
Suppression of debris-stimulated ovarian tumor growth by <t>PTUPB.</t> Percent survival of mice coinjected intraperitoneally with (A) paclitaxel- or (B) carboplatin-generated ID8 debris (9 × 105 dead cells) and ID8 living cells (1 × 106), or (C) coinjected orthotopically with paclitaxel-generated ID8 debris (9 × 105 dead cells) and ID8 living cells (1 × 106). Image shows representative orthotopic tumors on day 62 postinjection. (Scale bar,1 <t>cm.)</t> <t>Systemic</t> treatment with PTUPB (30 mg/kg/d) or control initiated 4 wk postinjection. n = 4–5 mice per group. Kaplan–Meier analysis and log-rank testing indicated significantly prolonged survival in mice treated with PTUPB compared with control in the (A) paclitaxel-generated (log-rank test = 9.70, *P = 0.0018) and (B) carboplatin-generated (log-rank test = 9.85, *P = 0.0017) debris-stimulated intraperitoneal ovarian tumor models, as well as the (C) paclitaxel-generated debris-stimulated orthotopic ovarian tumor model (log-rank test = 7.91, *P = 0.005).
Ptupb, supplied by Federation of European Neuroscience Societies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ptupb/product/Federation of European Neuroscience Societies
Average 90 stars, based on 1 article reviews
ptupb - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Suppression of debris-stimulated ovarian tumor growth by PTUPB. Percent survival of mice coinjected intraperitoneally with (A) paclitaxel- or (B) carboplatin-generated ID8 debris (9 × 105 dead cells) and ID8 living cells (1 × 106), or (C) coinjected orthotopically with paclitaxel-generated ID8 debris (9 × 105 dead cells) and ID8 living cells (1 × 106). Image shows representative orthotopic tumors on day 62 postinjection. (Scale bar,1 cm.) Systemic treatment with PTUPB (30 mg/kg/d) or control initiated 4 wk postinjection. n = 4–5 mice per group. Kaplan–Meier analysis and log-rank testing indicated significantly prolonged survival in mice treated with PTUPB compared with control in the (A) paclitaxel-generated (log-rank test = 9.70, *P = 0.0018) and (B) carboplatin-generated (log-rank test = 9.85, *P = 0.0017) debris-stimulated intraperitoneal ovarian tumor models, as well as the (C) paclitaxel-generated debris-stimulated orthotopic ovarian tumor model (log-rank test = 7.91, *P = 0.005).

Journal: Proceedings of the National Academy of Sciences of the United States of America

Article Title: Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor

doi: 10.1073/pnas.1803999116

Figure Lengend Snippet: Suppression of debris-stimulated ovarian tumor growth by PTUPB. Percent survival of mice coinjected intraperitoneally with (A) paclitaxel- or (B) carboplatin-generated ID8 debris (9 × 105 dead cells) and ID8 living cells (1 × 106), or (C) coinjected orthotopically with paclitaxel-generated ID8 debris (9 × 105 dead cells) and ID8 living cells (1 × 106). Image shows representative orthotopic tumors on day 62 postinjection. (Scale bar,1 cm.) Systemic treatment with PTUPB (30 mg/kg/d) or control initiated 4 wk postinjection. n = 4–5 mice per group. Kaplan–Meier analysis and log-rank testing indicated significantly prolonged survival in mice treated with PTUPB compared with control in the (A) paclitaxel-generated (log-rank test = 9.70, *P = 0.0018) and (B) carboplatin-generated (log-rank test = 9.85, *P = 0.0017) debris-stimulated intraperitoneal ovarian tumor models, as well as the (C) paclitaxel-generated debris-stimulated orthotopic ovarian tumor model (log-rank test = 7.91, *P = 0.005).

Article Snippet: Systemic treatment with PTUPB (30 mg/kg/d) or control was administered via miniosmotic pumps (Alzet Inc.) implanted into the peritoneum of the mice 4 wk postinjection.

Techniques: Generated